Stock Financial Ratios, Dividends, Split History

RGLS / Regulus Therapeutics Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price0.28
Volume1,260,600.00
Market Cap ($M)29.94
Enterprise Value ($M)20.20
Book Value ($M)22.88
Book Value / Share0.22
Price / Book1.32
NCAV ($M)12.22
NCAV / Share0.12
Price / NCAV2.47
Share Statistics
Common Shares Outstanding 103,959,103
Common Stock Shares Outstanding 103,955,147
Scoring Models
Piotroski F-Score0.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-2.04
Return on Assets (ROA)-0.71
Return on Equity (ROE)-1.28
Balance Sheet (mrq) ($M)
Assets62.08
Liabilities39.20
Quick Ration/a
Current Ratio1.66
Income Statement (mra) ($M)
Financingfrom Sale Proceeds Debt Agreement Revenues406,000,000.00
Revenues72,000.00
Operating Income-70.13
Net Income-71.91
Earnings Per Share Basic And Diluted-0.96
Earnings Per Share Basic-0.96
Earnings Per Share Diluted-0.96
Cash Flow Statement (mra) ($M)
Cash From Operations-58.77
Cash from Investing13.94
Cash from Financing13.94
Identifiers and Descriptors
CUSIP75915K101
Central Index Key (CIK)1505512
Related CUSIPS
75915K901 75915K951

Split History

Stock splits are used by Regulus Therapeutics Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon
RGLS : Regulus Therapeutics Stock Analysis and Research Report

2017-10-20 - Asif

Regulus Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing first-in-class drugs targeting micro RNAs to treat diseases with significant unmet medical need. Regulus was formed in 2007 when Alnylam Pharmaceuticals, Inc., or Alnylam, and Ionis Pharmaceuticals, Inc., or Ionis, contributed significant intellectual property, know-how and financial and human capital to pursue the development of drugs targeting micro RNAs pursuant to a license and collaboration agreement. Its most advanced program, under its strategic alliance with Sanofi, is RG-012, an anti-miR targeting miR-21 for the treatment of Alport syndrome, a life-threatening kidney disease driven by genetic mutations, currently with no approved therapy available. micro RNAs are naturally occurring ribonucleic acid, or RNA, molecules that play a critical role in regulating key biological pathways. Scientific research has shown that an imbalance, or dysregulation, of micro RNAs is dire...

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Related News Stories

Avon Products, Nevro Plunge into Tuesday’s 52-Week Low Club

2018-07-10 247wallst
July 10, 2018: Here are four stocks trading with heavy volume among 31 equities making new 52-week lows in Tuesday’s session. On the NYSE advancers and decliners were dead even and on the Nasdaq, decliners led advancers by about 1.4 to 1. (30-1)

Beleaguered Regulus Therapeutics Slashes 60 Percent of Workforce in New Corporate Restructuring

2018-07-10 biospace
Shares of Regulus Therapeutics saw something of a slight rally on Monday following a post-Independence Day corporate restructuring announcement that included the termination of 60 percent of its workforce, which caused a massive stock plummet.

Regulus Stock Plunges on Cash Concerns Despite Restructuring

2018-07-09 zacks
Regulus Therapeutics Inc.’s (RGLS - Free Report) shares plunged 52% on Jul 6 following the announcement of drastic restructuring initiatives to extend its cash runway. Although the plans announced are expected to save $20 million annually and support the company’s operations till mid-2019, investors remain skeptical about the company’s cash position and are wary of its pipeline progress. (2-0)

MetLife, MiMedx Group Fall into Friday’s 52-Week Low Club

2018-07-06 247wallst
July 6, 2018: Here are four stocks trading with heavy volume among 32 equities making new 52-week lows in Friday’s session. On the NYSE advancers led decliners by about 2.7 to 1 and on the Nasdaq, advancers led decliners by about 2.35 to 1. (129-1)

Regulus Axing 60% of Workforce, Pauses Patient Recruitment for Lead Program

2018-07-06 genengnews
Regulus Therapeutics has begun a restructuring that includes elimination of 60% of its workforce and a voluntary pause of its Phase I study for RGLS4326, designed to treat autosomal dominant polycystic kidney disease (pictured), following undisclosed “unexpected observations” in the 27-week mouse chronic toxicity study. [American Urological Association] (0-3)

CUSIP: 75915K101